Sign in
GL

GXO Logistics, Inc. (GXO)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered broad-based beats: revenue $2.977B (+21% YoY), adjusted EBITDA $163M, and adjusted diluted EPS $0.29, each above S&P Global consensus; GAAP diluted EPS was a loss of $0.81 driven by a $66M VAT accrual and other non-GAAP adjustments .
  • Reaffirmed FY2025 guidance: organic revenue growth 3–6%, adjusted EBITDA $840–$860M, adjusted diluted EPS $2.40–$2.60, and 25–35% EBITDA-to-FCF conversion; capital return accelerated with 2.8M shares repurchased under a $500M authorization .
  • Pipeline at a three-year high ($2.5B) and strategic wins including a landmark 10-year NHS Supply Chain contract (~$2.5B LTV) position healthcare as a growth vertical; $700M incremental revenue secured for 2025 and $300M for 2026 .
  • Near-term catalysts: sustained execution in automated start-ups, Wincanton integration synergies (limited in 2025; ramp thereafter), and AI-enabled warehouse productivity; management reaffirmed guidance despite macro/tariff volatility, FX largely hedged near term .

What Went Well and What Went Wrong

  • What Went Well

    • Record wins and pipeline: $228M new business signed; pipeline at $2.5B, diversified across geographies/verticals; NHS Supply Chain win, largest-ever (~$2.5B LTV) .
    • Execution and productivity: adjusted EBITDA $163M, aided by faster-than-expected ramp of new facilities and site-level productivity initiatives; AI pilots delivering early cost savings and multi‑x process productivity gains .
    • Guidance reaffirmed amid uncertainty: management reiterated FY2025 ranges and scenario-tested resilience to potential U.S. consumer softness; FX hedged for Q2/Q3 with expected 2026 tailwind .

  • What Went Wrong

    • GAAP loss driven by non-GAAP items: regulatory VAT accrual ($66M), transaction/integration ($22M), restructuring ($17M) pressured GAAP EPS to -$0.81 and operating margin to -1.9% .
    • Margin compression YoY: adjusted EBITDA margin fell to 5.5% (from 6.3%); direct OpEx mix stepped up (85.9% of revenue) reflecting Wincanton profile, with SG&A lower in that business pre‑integration .
    • U.K. volume softness: cited customer reactions to employment tax changes; offset by strength in North America and Continental Europe; free cash flow was negative (-$48M) on seasonal and acquisition impacts .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Billions)$3.157 $3.250 $2.977
Adjusted EBITDA ($USD Millions)$223 $251 $163
Adjusted EBITDA Margin %7.1% 7.7% 5.5%
GAAP Diluted EPS ($USD)$0.28 $0.83 ($0.81)
Adjusted Diluted EPS ($USD)$0.79 $1.00 $0.29
Operating Income (Loss) ($USD Millions)$81 $101 ($56)
Cash from Operations ($USD Millions)$198 $186 $29
Free Cash Flow ($USD Millions)$110 $127 ($48)

Actual vs S&P Global Consensus (Q1 2025):

MetricActualConsensusSurprise
Revenue ($USD Billions)$2.977 $2.931*+$0.046B
Adjusted EBITDA ($USD Millions)$163 $154.8*+$8.2M
Adjusted Diluted EPS ($USD)$0.29 $0.253*+$0.037

Values retrieved from S&P Global.*

Disaggregation by Geography (Q1 2025 vs Q1 2024):

Geography ($USD Millions)Q1 2024Q1 2025
United Kingdom$913 $1,391
United States$747 $752
Netherlands$218 $232
France$200 $186
Spain$129 $143
Italy$93 $95
Other$156 $178
Total$2,456 $2,977

Disaggregation by Industry (Q1 2025 vs Q1 2024):

Industry ($USD Millions)Q1 2024Q1 2025
Omnichannel retail$1,022 $1,422
Tech & consumer electronics$382 $393
Industrial & manufacturing$266 $362
Food & beverage$316 $314
Consumer packaged goods$295 $284
Other$175 $202
Total$2,456 $2,977

Key KPIs and Balance Sheet:

KPIQ1 2025Notes
New business wins ($USD Millions)$228 Signed in-quarter
Sales pipeline ($USD Billions)$2.5 Excludes Wincanton
Incremental revenue booked (2025/2026)$700M / $300M As of Q1
Share repurchases (shares)2.8M Under $500M authorization
Cash & equivalents ($USD Millions)$288 Excludes restricted cash
Total debt / Net debt ($USD Billions)$2.720 / $2.439 Net leverage 3.0x

Guidance Changes

MetricPeriodPrevious Guidance (Q4 2024)Current Guidance (Q1 2025)Change
Organic Revenue Growth (%)FY 20253%–6% 3%–6% Maintained
Adjusted EBITDA ($USD Millions)FY 2025$840–$860 $840–$860 Maintained
Adjusted Diluted EPS ($USD)FY 2025$2.40–$2.60 $2.40–$2.60 Maintained
EBITDA-to-FCF Conversion (%)FY 202525%–35% 25%–35% Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024, Q4 2024)Current Period (Q1 2025)Trend
AI/technology initiativesPilots in proactive replenishment, SKU dimensioning, order routing; 22 instances; multi‑x productivity gains First quarter cost savings realized; expanding modules and use cases (reverse logistics, cycle counting automation) Positive momentum; scaling
Supply chain/tariffs/macroTariff uncertainty noted; pipeline resilient; consumer volumes slightly positive in Q4 Customers requesting bonded warehouses, rebagging/retagging; limited near-term financial impact; scenario-tested guidance robustness Increasing complexity; GXO support
Healthcare vertical expansionLandmark health contract won; growth vector post-Clipper NHS Supply Chain 10-year ~$2.5B LTV; new Siemens Healthineers wins; accelerating healthcare footprint Step-change expansion
Wincanton integration/CMAAcquisition complete; awaiting CMA timing; synergies ~$55–58M targeted CMA conclusion expected “early summer”; potential small disposal; limited 2025 synergies (~£10M) then ramp Integration near commencement
Regional trendsContinental Europe strongest; U.S. improvement; U.K. softer post-budget North America strongest in Q1; Continental Europe rock-solid; U.K. softer on employment tax change, rebounding in Q2 Mixed; improving sequentially
FX and hedgingFX a headwind in 2024; 2025 effective tax higher Q2 near fully hedged; Q3 ~75%; protections around EUR/USD and GBP/USD; tailwind expected in 2026 if rates hold Managed near term; 2026 tailwind
Capital allocation/buybacksDeleveraging focus; M&A off near-term agenda 2.8M shares repurchased; $500M authorization; continue balancing repurchases vs growth/leverage Active repurchases; disciplined

Management Commentary

  • “We generated revenue of $3 billion, up 21% year over year, and delivered $163 million in adjusted EBITDA… We’ve finalized a landmark deal with England’s National Health Service Supply Chain… total lifetime value of about $2.5 billion.” — Malcolm Wilson, CEO .
  • “Our strong operating results were primarily driven by a faster-than-anticipated ramp-up of new facilities and of site level productivity initiatives… Excluding [charges], our adjusted net income was $34 million.” — Baris Oran, CFO .
  • “Over the past year, we've been piloting and launching our AI modules… we now have over 20 implementations live… In Q1, we’ve now seen our first cost savings… these cost savings will ramp up over the course of 2025.” — Kristine Kubacki, Chief Strategy Officer .

Q&A Highlights

  • Guidance resilience and scenario planning: Base case assumes flat volumes YoY; even with low-to-mid single-digit decline in U.S. consumer volumes in 2H, EBITDA range still attainable .
  • FX hedging strategy: Q2 2025 largely hedged; Q3 ~75%; more upside likely in 2026 if current FX levels persist .
  • NHS contract ramp: “Takeover in place” of ~8 locations, ~2,000 people, several hundred vehicles; not anticipating significant start-up costs; health sector pipeline expanding .
  • Macro/inventory and bonded warehouses: Elevated inventory in North America tech/fashion; bonded warehouse services requests increasing; financial impact currently immaterial .
  • Margin mix and Wincanton: Higher direct OpEx percentage due to Wincanton (with lower SG&A); profitability expected to lift post-integration; limited 2025 synergies (~£10M) .
  • VAT matter in Italy: Accrual of €61M (~$66M) expected to settle in 2025; add-back to adjusted EBITDA/EPS; no impact on 2025 adjusted tax rate (~25%) .

Estimates Context

  • Q1 2025 beats: revenue $2.977B vs $2.931B*, adjusted EBITDA $163M vs $154.8M*, adjusted EPS $0.29 vs $0.253*; drivers include faster start-up ramps and site productivity initiatives .
  • Street may revisit margin trajectory: management reiterated an acceleration of organic growth through 2025 (wins ~8%, churn ~-5%, pricing ~1.5%), with EBITDA ramp from maturing start-ups and integration synergies later in the year .
    Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Quality beat on all core P&L metrics (revenue, adjusted EBITDA, adjusted EPS) with reaffirmed FY guidance; execution offsets macro/tariff noise .
  • Near-term GAAP optics (loss) reflect one-time/regulatory items; non-GAAP adds are well disclosed and excluded from adjusted results (VAT accrual, transaction/integration, restructuring) .
  • Strategic contracts (NHS) and healthcare vertical expansion are durable growth catalysts; pipeline at multi-year highs supports organic acceleration into 2H and 2026 .
  • Wincanton integration approaching; limited 2025 synergies then step-up, with mix normalization (direct OpEx/SG&A) and cost synergies aiding margins .
  • AI-enabled warehouse initiatives beginning to translate to cost savings; compounding benefits expected as modules scale across sites .
  • FX risk contained near term via hedges; potential 2026 tailwind if rates hold; estimate models should reflect limited FX impact in 2025 .
  • Capital return is active (2.8M shares repurchased) while leverage remains manageable (net leverage 3.0x); balance sheet capacity supports disciplined growth and buybacks .